Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation

Journal of Clinical Gastroenterology

Volumn 46, Issue 9, 2012, Pages 789-795

  Wu, Wen Chieh ^a   Chiou, Yi You ^a,c   Hung, Hung Hsu ^a,c   Kao, Wei Yu ^a,b,c   Chou, Yi Hong ^a,c   Su, Chien Wei ^a,c   Wu, Jaw Ching ^a,c   Huo, Teh Ia ^c   Huang, Yi Hsiang ^a,c   Lee, Kuei Chuan ^a,c   Lin, Han Chieh ^a,c   Lee, Shou Dong ^c,d,e  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Taoyuan Branch   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

hepatocellular carcinoma; liver fibrosis; prognosis; radiofrequency ablation; splenic volume

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; PEGINTERFERON;

AGED; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CHEMOEMBOLIZATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; SPLEEN; SPLENOMEGALY; THROMBOCYTE COUNT; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SPLEEN; SPLENOMEGALY; SURVIVAL RATE; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84866256208     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31825ceeb5     Document Type: Article

References (40)

1. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239-245.
2. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474.
3. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(suppl 1):S20-S37.
4. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-773.
5. Kao WY, Chiou YY, Hung HH, et al. Risk factors for longterm prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. Eur J Gastroenterol Hepatol. 2011;23:528-536.
6. Rossi S, Ravetta V, Rosa L, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology. 2011;53:136-147.
7. Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007;17:684-692.
8. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151-1156.
9. Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a metaanalysis. J Hepatol. 2010;52:380-388.
10. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201-1209. (Pubitemid 40328091)
11. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82-89. (Pubitemid 351171044)
12. N'Kontchou G,Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50:1475-1483.
13. Hung HH, Chiou YY, Hsia CY, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79-86.
14. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510.
15. Su CW, Lei HJ, Chau GY, et al. The effect of age on the longterm prognosis of patients with hepatocellular carcinoma after resection surgery: a propensity score matching analysis. Arch Surg. 2012;147:137-144.
16. Kao WY, Su CW, Chau GY, et al. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg. 2011;35:858-867.
17. Kao WY, Chiou YY, Hung HH, et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol. 2012;46: 62-70.
18. Hung HH, Su CW, Lai CR, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4:691-699.
19. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890-897.
20. Li WX, Zhao XT, Chai WM, et al. Hepatitis B virus-induced liver fibrosis and cirrhosis: the value of liver and spleen volumetry with multi-detector spiral computed tomography. J Dig Dis. 2010;11:215-223.
21. Liu P, Li P, He W, et al. Liver and spleen volume variations in patients with hepatic fibrosis. World J Gastroenterol. 2009;15:3298-3302.
22. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
23. Prassopoulos P, Daskalogiannaki M, Raissaki M, et al. Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol. 1997;7:246-248. (Pubitemid 127538590)
24. Bezerra AS, D'Ippolito G, Faintuch S, et al. Determination of splenomegaly by CT: is there a place for a single measurement? Am J Roentgenol. 2005;184:1510-1513. (Pubitemid 43821827)
25. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. (Pubitemid 32844200)
26. Vallet-Pichard A,Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-36. (Pubitemid 47171918)
27. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526. (Pubitemid 36919874)
28. Su CW, Chan CC, Hung HH, et al. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol. 2009;43: 876-883.
29. Bonacini M, Hadi G, Govindarajan S, et al. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1997;92:1302-1304. (Pubitemid 27328588)
30. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42:282-292. (Pubitemid 41061080)
31. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011;5:625-634.
32. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997;4:199-208. (Pubitemid 127733511)
33. Bolognesi M, Merkel C, Sacerdoti D, et al. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis. 2002;34:144-150. (Pubitemid 34202075)
34. Ishibashi H, Higuchi N, Shimamura R, et al. Sonographic assessment and grading of spleen size. J Clin Ultrasound. 1991;19:21-25.
35. Hashimoto T, Sugawara Y, Tamura S, et al. Estimation of standard liver volume in Japanese living liver donors. J Gastroenterol Hepatol. 2006;21:1710-1713. (Pubitemid 44410883)
36. Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transplant. 2002;8:233-240. (Pubitemid 34257205)
37. Shiha G, Sarin SK, Ibrahim AE, et al. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2009;3:323-333.
38. Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8:877-883.
39. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010;105:1346-1353.
40. Lee IC, Chan CC, Huang YH, et al. Comparative analysis of noninvasive models to predict early liver fibrosis in hepatitis B e antigen-negative chronic hepatitis B. J Clin Gastroenterol. 2011;45:278-285.